CA9 and renal cell carcinoma: In a subcutaneous mouse model of human RCC, intratumoral injection of OAV-DEC plus intravenous infusion of CAIX-CAR-T significantly suppressed tumor growth, inhibition rate reaching 90%, whereas sole CAIX-CAR-T treatment achieved only 54% inhibition (Zhang et al., 2022).